Regen BioPharma Inc. (OTCMKTS:RGBP) Spikes

Double exposure of Scientist hand in glove with test tube. DNA research technology,making research in clinical laboratory,science laboratory research and development concept.

Regen BioPharma Inc. (OTCMKTS:RGBP)

Regen BioPharma Inc. (OTCMKTS:RGBP) shares gained 21.6% after the CEO, David Koos, provided an update on how they intend to pursue autoimmune indications by activating Nuclear Receptor NR2F6. According to the biopharmaceutical company, they believe they can unleash cancer-killing potential on patients’ immune systems by inhibiting the NRF6 nuclear receptor.

NR2F6 Development

Regen BioPharma Inc. (OTCMKTS:RGBP) is currently working on a rationale that will be used in the future to activate the NR2F6 nuclear receptor. The company has designed its program to work on small molecules to take advantage of reduced manufacturing costs as well as flexibility when it comes to dosing and routes of administration.

Currently, nine companies are working on programs designed to activate the immune checkpoints. Regen Biopharma is the only one working on utilizing the benefits of small molecules to activate immune checkpoints.

“Our program stands out because we are working with small molecules delivered in pill form. Other biotechnology companies are focused on antibodies that have much more cumbersome delivery methods (hospital stays with IV injections, etc.),” said Mr. Koos.

RGBP Stock Performance

Regen BioPharma Inc. (OTCMKTS:RGBP) has been on an impressive run ever since it announced it is working on activating the immune system to unleash cancer-killing potential. Over the past one month, the stock has gained more than 100% in the market as it continues to trade in an uptrend. The stock has trimmed all the losses accrued since the start of the year and is currently up by more than 10% for the year.

Renewed investor interest in the stock builds on growing confidence about the company’s NR2F6 nuclear receptor, as an important immune cell inhibitor and cancer stem cell differentiator. The company has already began a three-dimensional structure of the receptor.

Determining the structure of the receptor is essential as it will inform future work on medicinal chemistry. Such a discovery will also confirm the exact nature of the interaction between Regen BioPharma Inc. (OTCMKTS:RGBP)’s small molecules and NR2F6

“The three-dimensional x-ray structure program, coupled with our medicinal chemistry program will enhance Regen’s drug development process. These two programs linked together will give us a much clearer picture of what is actually happening at the molecular level,” said Mr. Koos.

Separately, Regen BioPharma Inc. (OTCMKTS:RGBP) has appointed former Eli Lilly executive Jean-Pierre Million to serve as Chairman of its newly formed business advisory board. The board is tasked with the responsibility of assisting the management team to evaluate partnership and licensing opportunities related to the company’s intellectual property including the NR2F6 program.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RGBP and receive breaking news on other hot stocks by signing up for our free newsletter!

Jack arrived in the USA from Scotland over 20 years ago to study chemistry. His studies led him to a job with a Fortune 500 company and then to a stint as an analyst for a private equity firm. After the 2008 market meltdown Jack returned to Scotland where he works full-time as an analyst and travel writer.

Our diverse staff has over 65 years of experience analyzing stocks, industry sectors, and economics. It is our goal to provide you with pertinent, useful information on a daily basis. We believe the stocks we cover represent a sector of the equity markets that often goes ignored. Your comments and suggestions are valued. We encourage you to contact us with any ideas that may help us improve.